Factors that influence long-term hematopoietic function following autologous stem cell transplantation

Bone Marrow Transplantation

Volumn 24, Issue 3, 1999, Pages 289-293

  Amigo, M L ^a   Del Canizo M C ^a   Caballero, M D ^a   Vazquez, L ^a   Corral, M ^a   Vidriales, B ^a   Brufau, A ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Autologous transplantation; CD34+ cells; CFU GM; Peripheral cytopenias

Indexed keywords

CD34 ANTIGEN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; COLONY FORMING UNIT GM; CYTOPENIA; FEMALE; HEMATOPOIESIS; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0032772373     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701886     Document Type: Article

References (27)

1. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
2. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051-1054.
3. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
4. Arnold R, Schmeiser T, Heit W et al. Hemopoietic reconstitution after bone marrow transplantation. Exp Hematol 1986; 14: 271-277.
5. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
6. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 2: 588-596.
7. Olivieri A, Offidani M, Montanari M et al. Factors affecting hematopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998; 83: 329-337.
8. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
9. Jagannath S, Vesole D, Glenn L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666-1672.
10. Schwella N, Siegert W, Beyer J et al. Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Ann Hematol 1995; 71: 227-234.
11. Haas R, Witt B, Mohle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 12: 3754-3761.
12. Bentley SA, Brecher ME, Powell E et al. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Transplant 1997; 19: 557-563.
13. Sheridan W, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
14. Peters W, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
15. To LB, Roberts MM, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
16. Langenmayer Y, Weaver C, Buckner CD et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241-246.
17. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303-310.
18. Bacigalupo A, Piaggio G, Podesta M et al. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 221-226.
19. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970; 36: 507-512.
20. Macedo A, Orfao A, Ciudad J et al. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for detection of minimal residual disease. Leukemia 1995; 9: 1896-1901.
21. Del Cañizo MC, Brufau A, Mota A et al. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica 1998; 83: 3-7.
22. Iscove NN, Sieher K, Witerhalter KH. Erythroid colony formation in culture of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concavalin. Am J Cell Physiol 1974; 83: 309-320.
23. Minden MD, Till JE, McCulloch EA. Proliferation state of blast progenitors in acute myeloblastic leukemia (AML). Blood 1978; 52: 592-600.
24. Pérez-Simón JA, Caballero MD, Corral M et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998; 38: 385-391.
25. Domenech J, Linassier C, Gihana E et al. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood 1995; 85: 3320-3327.
26. Gardner RE, Astle CM, Harrison DE. Hematopoietic precursor cell exhaustion is a cause of proliferative defect primitive hematopoietic stem cells (PHSC) after chemotherapy. Exp Hematol 1997; 25: 495-501.
27. Cañizo MC, López N, Caballero MD et al. Hematopoietic damage persists one year after peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 901-905.